EXPERIMENTAL IMMUNOLOGY
The effect of pentoxifylline on L-1 sarcoma tumor growth and angiogenesis in Balb/c mice
Submission date: 2017-03-19
Acceptance date: 2017-03-27
Publication date: 2017-07-26
Cent Eur J Immunol 2017;42(2):131-139
KEYWORDS
ABSTRACT
Methyloxantines are present in many herbs and vegetal foods, among them in tea, coffee and chocolate. Previous studies revealed that theophylline and theobromine have anti-angiogenic properties. Anti-tumor properties of theobromine were also described. Pentoxifylline (3,7-dimethyl-1-(5-oxohexyl)xanthine, PTX) is a synthetic xanthine derivative. It is a phosphodiesterase inhibitor and has various anti-inflammatory abilities. Pentoxifylline is widely used in therapy of inflammatory arterial diseases such as intermittent claudication of upper and lower limbs as well as in coronary heart disease.
The aim of our research was to evaluate the effect of pentoxifylline (individually and in combination with non-steroidal anti-inflammatory drug sulindac), on L-1 sarcoma angiogenic activity and tumor formation in syngeneic Balb/c mice.
Pre-incubation of tumor cells for 90 min with various PTX concentrations resulted in dose-dependent decrease of their ability to induce newly-formed blood vessels after transplantation into the skin of recipient mice. Administration of PTX to mice, recipients of tumor cells, slows tumor growth and reduces its volume. Synergistic inhibitory effect of PTX and sulindac, expressed as % of tumors sixth and thirteen day after subcutaneous grafting of L-1 sarcoma into syngeneic Balb/c mice, was observed.
The aim of our research was to evaluate the effect of pentoxifylline (individually and in combination with non-steroidal anti-inflammatory drug sulindac), on L-1 sarcoma angiogenic activity and tumor formation in syngeneic Balb/c mice.
Pre-incubation of tumor cells for 90 min with various PTX concentrations resulted in dose-dependent decrease of their ability to induce newly-formed blood vessels after transplantation into the skin of recipient mice. Administration of PTX to mice, recipients of tumor cells, slows tumor growth and reduces its volume. Synergistic inhibitory effect of PTX and sulindac, expressed as % of tumors sixth and thirteen day after subcutaneous grafting of L-1 sarcoma into syngeneic Balb/c mice, was observed.
REFERENCES (42)
1.
Bałan BJ, Siwicki AK, Pastewka K, et al. (2017): Synergistic activity for some natural and synthetic inhibitors of angiogenesis induced by mice sarcoma L-1 and human kidney cancer cells (RCC). Adv Exper Med Biol, DOI: 10.1007/5584_2017_17.
2.
Skopiński P, Żukowska M, Małkowska-Zwierz W, et al. (1993): The effect of TPP, theophylline, and theobromine on the angiogenic activity of mononuclear leukocytes obtained from diabetic patients with proliferative retinopathy. Acta Pol Pharm 50: 409-411.
3.
Gil M, Skopińska-Różewska E, Radomska D, et al. (1993): Effect of purinergic receptor antagonists suramin and theobromine on tumor-induced angiogenesis in Balb/c mice. Folia Biol (Praha) 39: 63-68.
4.
Skopinska-Rózewska E, Janik P, Przybyszewska M, et al. (1998): Inhibitory effect of theobromine on induction of angiogenesis and VEGF mRNA expression in v-raf transfectants of human urethelial cells HCV-29. Int J Mol Med 2: 649-701.
5.
Barcz E, Sommer E, Sokolnicka I, et al. (1998): The influence of theobromine on angiogenic activity and proangogenic cytokines production of human ovarian cancer cells. Oncol Rep 5: 517-520.
6.
Barcz E, Sommer E, Janik P, et al. (2000): Adenosine receptor antagonism causes inhibition of angiogenic activity of human ovarian cancer cells. Oncol Rep 7: 1285-1291.
7.
D’Hellencourt CL, Diaw L, Cornillet P, Guenounou M (1996): Differential regulation of TNF alpha, IL-1 beta, IL-6, IL-8, TNF beta, and IL-10 by pentoxifylline. Int J Immunopharmacol 18: 739-748.
8.
Mandell GL (1995): Cytokines, phagocytes, and pentoxifylline. J Cardiovasc Pharmacol 25 (Suppl 2): S20-22.
9.
Barros Mendes J, Peixoto Campos P, Rocha MA, Passos Andrad S (2009): Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice. Life Sci 84 (15-16): 537-543.
10.
Pammi M, Haque KN (2015): Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst Rev 3: CD004205.
11.
Zein CO, Lopez R, Fu X, et al. (2012): Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: New evidence on the potential therapeutic mechanism. Hepatology (Baltimore, Md) 56: 1291-1299.
12.
Li H, Tan G, Tong L, et al. (2016): Pentoxifylline inhibits pulmonary inflammation induced by infrarenal aorticcross-clamping dependent on adenosine receptor A2A. Amer J Translational Res 8: 2210-2221.
13.
Schulzke SM, Kaempfen S, Patole SK (2014): Pentoxifylline for the prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 11: CD010018.
14.
Mohammadpour AH, Falsoleiman H, Shamsara J, et al. (2014): Pentoxifylline decreases serum level of adhesion molecules in atherosclerosis patients. Iranian Biomed J 18: 23-27.
15.
Thursz MR, Richardson P, Allison M, et al. (2015): Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 372: 1619-1628.
16.
Vege SS, Atwal T, Bi Y, et al. (2015): Pentoxifylline treatment in severe acute pancreatitis: a pilot, double-blind, placebo-controlled, randomized trial. Gastroenterology 149: 318-320.
17.
Sunil VR, Vayas KN, Cervelli JA, et al. (2014): Pentoxifylline Attenuates Nitrogen Mustard-induced Acute Lung Injury, Oxidative Stress and Inflammation. Exp Mol Pathol 97: 89-98.
18.
Rainsford KD (2010): Cardiovascular adverse reactions from NSAIDs are more than COX-2 inhibition alone. Rheumatology (Oxford) 49: 834-836,.
19.
Kearney PM, Baigent C, Godwin J, et al. (2006): Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. BMJ 332: 1302-1305.
20.
Graham DJ (2006): COX-2 inhibitors, other NSAIDs, and cardiovascular risk; the seduction of common sense. JAMA 296: 1653-1656.
21.
Koren G, Florescu A, Costei AM, et al. (2006): Nonsteroidal anti-inflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother 40: 824-829.
22.
Skopinska-Różewska E, Piazza GA, Sommer E, et al. (1998): Inhibition of angiogenesis by sulindac and its sulfone metabolite (FGN-1): a potential mechanism for their antineoplastic properties. Int J Tissue Reactions 20: 85-89.
23.
Flis S, Sołtysiak-Pawluczuk D, Jędrych A, et al. (2006): Antiangiogenic effect of sulindac sulfide could be secondary to induction of apoptosis and cell cycle arrest. Anticancer Res 26: 3033-3041.
24.
Liou JY, Wu CC, Chen BR, et al. (2008): Nonsteroidal anti-inflammatory drugs induced endothelial apoptosis by perturbing peroxisome proliferator-activated receptor – transcriptional pathway. Mol Pharmacol 74: 1399-1406.
25.
Skopiński P, Bałan BJ, Kocik J, et al. (2013): Inhibitory effect of herbal remedy PERVIVO and anti-inflammatory drug sulindac on L-1 sarcoma tumor growth and tumor angiogenesis in Balb/c mice. Mediators Inflamm. Article ID 289789, DOI: dx.doi.org /10.1155/ 2013/ 289/789.
26.
Lynch PM (2016): Chemoprevention of familial adenomatous polyposis. Fam Cancer 15: 467-475.
27.
Gong EY, Shin YJ, Hwang IY, et al. (2016): Combined treatment with vitamin C and sulindac synergistically induces p53- and ROS-dependent apoptosis in human colon cancer cells. Toxicol Lett 258: 126-133.
28.
Haanen C (2001): Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs 2: 677-683.
29.
Samadder NJ, Neklason DW, Boucher KM, et al. (2016): Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial. JAMA 315: 1266-1275.
30.
Tinsley HN, Gary BD, Thaiparambil J, et al. (2010): Colon tumour cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev Res (Phila) 3: 1303-1313.
31.
Li YX, Sun LQ, Weber-Johnston K, et al. (1999): Potentiation of cytotoxicity and radiosensitization of (E)-2-deoxy-2 (fluoromethylene) cytidine by pentoxifylline in vitro. Int J Cancer 80: 155-160.
32.
Kim SH, Khil MS, Ryu S, Kim JH (1993): Enhancement of radiation response on human carcinoma cell lines in culture by pentoxifylline. Int J Radiat Oncol 25: 61-65.
33.
Mastrandrea NJ (2014): Pentoxifylline as an adjuvant treatment in renal cell carcinoma. http://hdl.handle.net/10150/33....
34.
Hernandez-Florez G, Ortiz-Lazareno PC, Lerma-Diaz JM, et al. (2011): Pentoxifylline sensitizes human cervical tumor cells to cisplatin-induced apoptosis by suppressing NF-kappa B and decreased cell senescence. BMC Cancer 11: 483.
35.
Gude RP, Binda MM, Boquete AL, Bonfil RD (2001): Inhibition of endothelial cell proliferation and tumor-induced angiogenesis by pentoxifylline. J Cancer Res Clin Oncol 127: 625-630.
36.
Nathan JR, Lakshmanan G, Michael FM, et al. (2016): Expression of adenosine receptors and VEGF during angiogenesis and its inhibition by pentoxifylline – a study using zebrafish model. Biomed Pharmacother 84: 1406-1418.
37.
Amirkhosravi A, Warnes G, Biggerstaff J, et al. (1997): The effect of pentoxifylline on spontaneous and experimental metastasis of the mouse neuro2a neuroblastoma. Clin Exp Metast 15: 453-461.
38.
Kamran MZ, Gude ROP (2013): Pentoxifylline inhibits melanoma tumor growth and angiogenesis by targeting STAT3 signaling pathway. Biomed Pharmacother 67: 399-405.
39.
Lazarczyk M, Grzela T, Niderla J, et al. (2004): Differential influence of pentoxifylline on murine colon adenocarcinoma- and melanoma- derived metastatic tumor development in lungs. Oncol Rep 11: 1121-1125.
40.
Grzela T, Lazarczyk M, Niderla J, et al. (2003): Pentoxifylline promotes development of murine colon adenocarcinoma-derived metastatic tumors in liver. Oncol Rep 10: 1805-1809.
41.
Lazarczyk M, Grzela T, Niderla J, et al. (2003): Pentoxifylline inhibits leukocyte infiltration and splenocyte cytotoxicity against murine colon adenocarcinoma. Oncol Rep 10: 839-843.
42.
Lazarczyk M, Grzela T, Korczak-Kowalska G, et al. (2002): Pentoxifylline inhibits perforin-dependent natural cytotoxicity in vitro. Oncol Rep 9: 423-426.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
